Status:
COMPLETED
The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Metabolism and Nutrition Disorder
Obesity
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the efficacy of liraglutide to induce body weight loss and the purpose of the extension is to evaluate the long te...
Eligibility Criteria
Inclusion
- Body Mass Index (BMI) greater than or equal to 30.0 or lesser than or equal to 40.0 kg/m2
- Stable body weight (less than 5% selfreported change within the last 3 months)
Exclusion
- Obesity induced by drug treatment
- Use of approved drugs for weight lowering intervention (e.g. orlistat, sibutramin, rimonabant) within the last 3 months prior to entering trial
- Type 1 or type 2 diabetes
Key Trial Info
Start Date :
January 10 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2009
Estimated Enrollment :
564 Patients enrolled
Trial Details
Trial ID
NCT00422058
Start Date
January 10 2007
End Date
April 30 2009
Last Update
November 1 2017
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Edegem, Belgium, 2650
2
Novo Nordisk Investigational Site
Prague, Czechia, 116 94
3
Novo Nordisk Investigational Site
Prague, Czechia, 128 08
4
Novo Nordisk Investigational Site
Århus C, Denmark, 8000